SCHEMBL6135397

SCHEMBL6135397

Cc1ccc(S(=O)(=O)NC(=O)c2ccc3[nH]c(C)c(Cc4ccc(OCC5CCCCC5)cc4Cl)c3c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 3/20 0.51
BCL2L1 Q07817 1/20 0.51
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
LGALS8 O00214 2/20 0.38
LGALS3 P17931 1/20 0.38
PTGS2 P35354 1/20 0.37
CYSLTR1 Q9Y271 2/20 0.36
CYSLTR2 Q9NS75 1/20 0.36
PTPN5 P54829 1/20 0.36
CHRNA7 P36544 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SCN9A Q15858 2/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
HRH1 P35367 1/20 0.36
CCR3 P51677 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319106 0.88 MAPT (0.45) MCL1BCL2L1LGALS8LGALS3PTGS2
SCHEMBL6322473 0.84 SCN9A (0.41) MCL1BCL2L1PTGS2CYSLTR1CYSLTR2
SCHEMBL6318760 0.84 HPGD (0.45) PTPN5RAB9AMEN1KMT2ALMNA
SCHEMBL6319268 0.84 PTPN5 (0.52) PTPN5RAB9AMEN1KMT2APOLB
SCHEMBL6318392 0.84 MCL1 (0.49) MCL1BCL2L1PTGS2PTPN5
SCHEMBL5881768 0.82 FLT1 (0.51) PTGS2
SCHEMBL6319512 0.81 MGAM (0.43) PTGS2
SCHEMBL6321295 0.81 PTGS2 (0.43) LGALS8LGALS3PTGS2PTPN5LMNA
SCHEMBL6328588 0.80 MCL1 (0.49) MCL1BCL2L1PTGS2PTPN5POLB
SCHEMBL5881812 0.80 FLT1 (0.52) MCL1BCL2L1PTGS2PTPN5RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
WO-2005082414-A2 CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT ASTELLAS PHARMA INC. (JP) 2005-09-09 WO disclosed
US-20050197376-A1 Concomitant drugs FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-09-08 US disclosed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A MCL1 3761/4885BCL2L1 2853/4885ITGB3 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.